Telix Pharmaceuticals' Form 6-K: Major European Approval for Illucix Announced!

Here are the key insights extracted from the provided section of the financial report (Form 6-K) for Telix Pharmaceuticals Limited:

1. Company Information:

• Name: Telix Pharmaceuticals Limited
• Address: 55 Flemington Road, North Melbourne, Victoria 3051, Australia
• Commission File Number: 001-42128

2. Filing Date:

• The report was filed on January 17, 2025.

3. Purpose of Filing:

• This Form 6-K is a report of a foreign private issuer filed in accordance with the Securities Exchange Act of 1934.

4. Content of the Filing:

• The filing includes a significant announcement regarding the approval of Illucix, which is noted to have received European approval.
• The announcement was originally made to the Australian Securities Exchange (ASX) on the same date and is referenced as Exhibit 99.1.

5. Approval Significance:

• The European approval of Illucix represents a key milestone for Telix Pharmaceuticals, likely impacting its market presence and potential revenue streams in Europe.

6. Signatory Information:

• The report is signed by Genevieve Ryan, who holds the title of Company Secretary.

This information is critical as it highlights a significant regulatory approval for the company, indicating potential growth opportunities and strategic developments in its product offerings.